Inclisiran is an innovative lipid-lowering medication that works by harnessing the body's natural RNA interference (RNAi) pathway. It specifically targets the messenger RNA (mRNA) of the PCSK9 protein, which plays a crucial role in the regulation of cholesterol levels. By inhibiting PCSK9, inclisiran increases the number of LDL receptors on liver cells, thereby enhancing the clearance of LDL-C from the bloodstream.
